Table 2.

Neuropsychological test scores for cognitive assessment relative to both study groups at baseline, 16 and 32 weeks. Data are presented as mean ± SD and p-values derived from GLM repeated-measures

Variables	No treatment (N = 14)	Exenatide (N = 17)	GLM p-values
			Time	Treatment	Time*treatment
MMSE			0.64	0.10	0.12
Baseline	26.1 ± 1.8	25.9 ± 1.3
16 weeks	27.1 ± 2.4	25.8 ± 3.8
32 weeks	27.2 ± 2.1	24.6 ± 5.0
CDR			0.28	0.51	0.65
Baseline	0.30 ± 0.32	0.26 ± 0.26
16 weeks	0.18 ± 0.25	0.27 ± 0.26
32 weeks	0.29 ± 0.26	0.35 ± 0.34
GDS			0.54	0.4	0.54
Baseline	2.5 ± 2.8	2.2 ± 2.0
16 weeks	3.1 ± 2.7	2.2 ± 2.5
32 weeks	2.4 ± 2.1	1.9 ± 1.7
NPI			0.62	0.42	0.31
Baseline	10.4 ± 11.3	5.8 ± 4.1
16 weeks	8.7 ± 8.0	6.8 ± 5.7
32 weeks	7.9 ± 5.5	7.5 ± 5.7
IADL			0.02*	0.04*	0.08
Baseline	1.00 ± 0	0.99 ± 0.05
16 weeks	0.99 ± 0.03	0.94 ± 0.11
32 weeks	0.99 ± 0.04	0.89 ± 0.16
Phonemic fluency			0.97	0.25	0.18
Baseline	30.3 ± 11.1	29.0 ± 13.0
16 weeks	31.6 ± 10.9	27.2 ± 13.7
32 weeks	33.9 ± 11.1	27.1 ± 12.6
Semantic fluency			0.30	0.04*	0.03*
Baseline	30.0 ± 8.0	26.0 ± 9.7
16 weeks	31.9 ± 6.4	25.2 ± 10.5
32 weeks	31.9 ± 6.8	23.6 ± 10.6